Literature DB >> 29528436

Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients.

Kai-Henrik Peiffer1,2, Lisa Kuhnhenn1,2, Bingfu Jiang2, Antonia Mondorf1, Johannes Vermehren1, Viola Knop1, Simone Susser1, Dirk Walter1, Julia Dietz1, Gert Carra2, Fabian Finkelmeier1, Stefan Zeuzem1, Christoph Sarrazin1,3, Eberhard Hildt2,4.   

Abstract

Background: Hepatitis B virus (HBV) surface proteins (HBsAg) coat the viral particle and form subviral particles (SVPs). Loss of HBsAg represents a functional cure and is an important treatment goal.
Methods: We analyzed the impact of the HBV genotypes A-E and pre-S mutations on SVP expression in hepatitis B virus e antigen (HBeAg)-negative chronic HBV-infected patients. A HBV genome harboring a preS1-deletion was analyzed in hepatoma cells.
Results: We observed a genotype-specific ratio of the 3 surface proteins (SHBs/MHBs/LHBs), reflecting differences in the morphology and composition of SVPs. Deletions/mutations in the preS1/preS2 domain, detected in released viral genomes, did not affect the molecular weight of MHBs and LHBs in these patients. In contrast, LHB molecular weight was altered in vitro using an HBV genome harboring a preS1-deletion derived from one of these patients.
Conclusion: Differences in composition of SVPs may result in genotype-specific immunogenicity and pathogenesis. In the patients with preS-mutations, secreted HBsAg and released viral genomes cannot be derived from the same genetic source. As viral genomes are derived from covalently closed circular DNA (cccDNA), HBsAg is presumably derived from integrated DNA. This important HBsAg source should be considered for novel antiviral strategies in HBeAg-negative chronic HBV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528436     DOI: 10.1093/infdis/jiy119

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Hepatitis B Virus Integration into Transcriptionally Active Loci and HBV-Associated Hepatocellular Carcinoma.

Authors:  Maria Bousali; Timokratis Karamitros
Journal:  Microorganisms       Date:  2022-01-24

2.  Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection.

Authors:  Romina Salpini; Arianna Battisti; Lorenzo Piermatteo; Luca Carioti; Olympia E Anastasiou; Upkar S Gill; Domenico Di Carlo; Luna Colagrossi; Leonardo Duca; Ada Bertoli; Katia Yu La Rosa; Lavinia Fabeni; Alessandra Iuvara; Vincenzo Malagnino; Carlotta Cerva; Miriam Lichtner; Claudio M Mastroianni; Giuseppe Maria De Sanctis; Maurizio Paoloni; Massimo Marignani; Caterina Pasquazzi; Nerio Iapadre; Giustino Parruti; Jacopo Vecchiet; Loredana Sarmati; Massimo Andreoni; Mario Angelico; Sandro Grelli; Patrick T Kennedy; Jens Verheyen; Stefano Aquaro; Francesca Ceccherini Silberstein; Carlo Federico Perno; Valentina Svicher
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

3.  Abundance of Noncircular Intrahepatic Hepatitis B Virus DNA May Reflect Frequent Integration Into Human DNA in Chronically Infected Patients.

Authors:  Gustaf E Rydell; Simon B Larsson; Kasthuri Prakash; Maria Andersson; Heléne Norder; Kristoffer Hellstrand; Gunnar Norkrans; Magnus Lindh
Journal:  J Infect Dis       Date:  2022-06-01       Impact factor: 7.759

4.  Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2022-05-31       Impact factor: 5.818

5.  A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype.

Authors:  Sébastien Eymieux; Christophe Hourioux; Julien Marlet; Alain Moreau; Romuald Patient; Louis d'Alteroche; Catherine Gaudy-Graffin; Emmanuelle Blanchard; Philippe Roingeard
Journal:  J Viral Hepat       Date:  2022-06-07       Impact factor: 3.517

6.  Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance.

Authors:  Xiao Lin; Yanhong Zheng; Hong Li; Junfeng Lu; Shan Ren; Yisi Liu; Xiaoxiao Wang; Sujun Zheng; Lina Ma; Zhenhuan Cao; Xinyue Chen
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

7.  Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients.

Authors:  Ran Hao; Kuanhui Xiang; Yan Shi; Dong Zhao; Huifang Tian; Baohong Xu; Yufang Zhu; Huan Dong; Hai Ding; Hui Zhuang; Jie Hu; Tong Li
Journal:  Viruses       Date:  2019-01-18       Impact factor: 5.048

8.  Enigmatic PreS deletions in hepatitis B virus DNA.

Authors:  Wolfram H Gerlich; Dieter Glebe
Journal:  Virus Genes       Date:  2020-11-05       Impact factor: 2.332

9.  Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers.

Authors:  Kai-Henrik Peiffer; Catrina Spengler; Michael Basic; Bingfu Jiang; Lisa Kuhnhenn; Wiebke Obermann; Tobias Zahn; Mirco Glitscher; Alessandro Loglio; Floriana Facchetti; Gert Carra; Alica Kubesch; Johannes Vermehren; Viola Knop; Christiana Graf; Julia Dietz; Fabian Finkelmeier; Eva Herrmann; Jonel Trebicka; Arnold Grünweller; Stefan Zeuzem; Christoph Sarrazin; Pietro Lampertico; Eberhard Hildt
Journal:  JCI Insight       Date:  2020-11-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.